New Path Selected for Future Medicines Accelerator

New Path have been selected for the Future Medicines Accelerator, delivered by LYVA Labs and funded by Innovate UK.
Over the next few months, we’ll be developing our synthetic protein technology with expert support and mentorship from leaders in health and life sciences for a new application in radioligand therapy.

The Future Medicines Accelerator, delivered by LYVA Labs and funded by Innovate UK, supports UK SMEs developing the next generation of advanced therapeutics.
Through tailored mentoring, expert-led modules, and commercialisation support, the programme helps companies turn scientific breakthroughs into viable business opportunities.

New Path Awarded Second Innovate UK Grant

New Path is delighted to announce that it has won a second grant from Innovate UK Biomedical Catalyst to further develop its novel PS targeting tumour agnostic drug conjugates for hard-to-treat cancers including colon and pancreas. Colon cancer and pancreatic cancer affect more than 1.4 million people every year and have a very poor prognosis, particularly when diagnosis is late. The grant will be used to demonstrate efficacy of New Path’s lead candidate in a range of solid tumours as well as to further develop back up series of synthetic drug conjugates.

About Innovate UK 

Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

Innovate UK: inspiring business innovation. 

New Path Gets Grant Funding From Innovate UK Cancer Therapeutics

New Path is delighted to announce that it has won grant funding from Innovate UK Cancer Therapeutics (Biomedical Catalyst) to further develop it’s novel PS targeting tumour agnostic drug conjugates for hard-to-treat cancers including colon and pancreas. Colon cancer and pancreatic cancer affect more than 1.4 million people every year and have a very poor prognosis, particularly when diagnosis is late. The grant will be used to optimise New Path’s molecules to improve efficacy in-vivo.

About Innovate UK 

Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

Innovate UK: inspiring business innovation. 

New Path is Selected for Cancer Research Horizons & Innovate UK Oncology Accelerator

New Path is delighted to have been selected an oncology accelerator programme funded by Cancer Research Horizons and Innovate UK. The selection process was highly competative with just eight companies selected from over one hundred applications. The accelerator will assist in the development of New Path’s tumour agnostic drug conjugate programme through expert advice, pharma interaction and entrepreneurship and innovation training from professors at the UC Berkley UC Haas School of Business

New Path Raises Pre-Seed Funding

New Path Molecular is delighted to announce the closing of a pre-seed round to fund the proof of concept for our phosphatidylserine targeting cancer therapy. The round was lead by previous investors Deepbridge Capital. The team are delighted to be pushing forward this project which was started in collaboration with the late Prof Michael Wakelham.

New Path and Prof Wakelam Win Funding for Cancer Project

New Path Molecular and Prof Michael Wakelam, Director of the Babraham Institute, have been awarded funding from the Babraham Campus Collaboration Fund to investigate interactions between lanthipeptides and cancer cell membranes. This fund supports the development of collaborative partnerships, with commercial potential, between Babraham Institute researchers and companies on Campus. It will finance translational studies and staff exchanges to facilitate the pump priming of future collaborative grant applications and the transfer of knowledge, skills and technology within the Babraham Research Campus.

The aim of the study will be to investigate interactions between lipids in cancer cell membranes and a class of cyclic peptides. The composition of the cell wall of cancer cells is abnormal relative to normal cells and targeting this may unlock a route to selective cancer therapies.

We are excited to be able to access Prof Wakelam’s deep understanding of lipid membranes and to pair it with New Path’s expertise in the synthesis of lanthipeptide based functional molecules.